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Background:  We  explore  the  factor  structure  of  DSM-5  cannabis  use  disorders,  examine  its  prevalence
across  European-  and  African-American  respondents  as  well  as  its genetic  underpinnings,  utilizing  data
from  a genome-wide  study  of  single  nucleotide  polymorphisms  (SNPs).  We  also  estimate  the  heritability
of  DSM-5  cannabis  use  disorders  explained  by these  common  SNPs.
Methods: Data  on  3053  subjects  reporting  a lifetime  history  of cannabis  use  were  utilized.  Exploratory  and
conﬁrmatory  factor  analyses  were  conducted  to  create  a  factor  score,  which  was  used  in  a  genome-wide
association  analysis.  p-values  from  the  single  SNP  analysis  were  examined  for evidence  of gene-based
association.  The  aggregate  effect  of  all  SNPs  was  also  estimated  using  Genome-Wide  Complex  Traits
Analysis.
Results:  The  unidimensionality  of  DSM-5  cannabis  use  disorder  criteria  was  demonstrated.  Comparing
DSM-IV  to DSM-5,  a  decrease  in  prevalence  of  cannabis  use  disorders  was  only  noted  in  European-
American  respondents  and  was  exceedingly  modest.  For  the  DSM-5  cannabis  use  disorders  factor  score,
no  SNP  surpassed  the  genome-wide  signiﬁcance  testing  threshold.  However,  in  the  European-American
subsample,  gene-based  association  testing  resulted  in  signiﬁcant  associations  in 3  genes  (C17orf58,  BPTF
and  PPM1D)  on  chromosome  17q24.  In aggregate,  21%  of  the  variance  in  DSM-5  cannabis  use  disorders
was  explained  by the  genome-wide  SNPs;  however,  this  estimate  was  not  statistically  signiﬁcant.
Conclusions: DSM-5  cannabis  use  disorder  represents  a unidimensional  construct,  the  prevalence  of  which
is  only  modestly  elevated  above  the  DSM-IV  version.  Considerably  larger  sample  sizes  will  be required  to
identify  individual  SNPs  associated  with  cannabis  use disorders  and  unequivocally  establish  its  polygenic
underpinnings. Supplementary material can be found by accessing the online version of this
aper  at http://dx.doi.org and by entering doi:...
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1. Introduction
Cannabis is the most commonly used illicit psychoactive sub-
stance in developed nations (Degenhardt and Hall, 2012). While
a majority of cannabis users do not report problems, 10–30%
of those who ever use cannabis meet criteria for a lifetime
history of cannabis abuse or dependence as deﬁned by the
fourth edition of the Diagnostic and Statistical Manual (DSM-IV;
American Psychiatric Association, 1994). Recently, changes to the
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iagnostic criteria for substance use disorder have been made in
SM-5 (American Psychiatric Association, 2013), including several
or the diagnosis of cannabis use disorders (Hasin et al., 2013).
cross the broad range of substance use disorders, (i) the distinction
etween abuse and dependence has been replaced by a unidimen-
ional symptom count, with endorsement of 2 or more symptoms
esulting in a DSM-5 diagnosis of substance use disorder (endorse-
ent of speciﬁc numbers of symptoms deﬁne a mild, moderate
r severe diagnosis); (ii) the DSM-IV criterion of legal problems
as been eliminated from the diagnostic repertoire; and (iii) a new
riterion for the DSM-5, craving (a long held substance depend-
nce criterion in the International Classiﬁcation of Disease, ICD)
as been added. More speciﬁcally for cannabis, withdrawal is now
 criterion. A wealth of psychometric evaluations in epidemiologi-
al (Agrawal et al., 2008; Compton et al., 2009; Gillespie et al., 2005;
artman et al., 2008; Hasin et al., 2012, 2008; Langenbucher et al.,
004; Lynskey and Agrawal, 2007; Martin et al., 2006; Piontek et al.,
011; Wu  et al., 2009, 2012) and clinical samples (Budney, 2006;
udney and Hughes, 2006) support these recommendations; how-
ver, the impact of these revisions on the prevalence of cannabis
se disorders under the new DSM-5 classiﬁcation remains largely
nexplored. A recent study of Australian adults found a modest
eduction in the rate of cannabis use disorder with the transition
rom DSM-IV to DSM-5 (Mewton et al., 2013), while another study
f individuals with substance use disorders noted a modest increase
f 4% (Peer et al., 2013).
Twin  studies indicate that 50–60% of the variation in cannabis
se disorders (abuse/dependence, variously deﬁned using DSM-
IIR, DSM-IV and ICD) can be attributed to heritable inﬂuences
Verweij et al., 2010). Despite this robust heritability estimate,
ssociation studies for cannabis use disorders have largely failed
o identify genetic variants of signiﬁcant and replicable effect. A
rior genome-wide association study (GWAS) of DSM-IV cannabis
ependence, conducted in the sample used in this study, failed to
dentify genetic variants at a statistically signiﬁcant level (Agrawal
t al., 2011b). This has resulted in speculation regarding the bio-
ogical underpinnings of cannabis use disorders; in particular, the
uestion of whether common variation available in commercially
vailable genome-wide arrays captures it (Sullivan et al., 2012).
Aggregating  the effects of all single nucleotide polymorphisms
SNPs) on commercial arrays might quantify the overall role of com-
on  SNPs as well as causal variants in linkage disequilibrium (LD)
able 1
revalence (%) of individual DSM-IV and proposed DSM-5 criteria for cannabis use
isorder in 3053 lifetime cannabis users of European-American (EA) and African-
merican  (AA) ancestry.
Males Females
EA AA EA AA
Role obligations 26.0a 25.8a 10.0b 13.2b
Hazard 49.2 37.3 21.8 16.8
Legal 4.8a 3.2a 1.4b 1.4b
Social/Interpersonal 31.3a 26.9a 14.2b 13.8b
Tolerance 34.0a 32.5a 13.2 17.2
Withdrawal 21.2a 24.8a 9.6 14.6
Larger/Longer 26.5 35.8 13.7 19.4
Quit 29.1 35.1 13.9 23.8
Time spent 34.4a 37.3a 12.9 20.8
Give up 24.3a 21.6a 8.4b 10.4b
Problems 26.1a 27.2a 14.6b 16.8b
Craving 17.9a 19.8a 7.0 12.0
DSM-IV abuse/dependence 55.4a 52.6a 28.1b 30.2b
DSM-5 use disorder 51.1a 52.6a 25.1 31.8
a Prevalence with the same superscripts could be statistically equated to each
ther at p > 0.05.
b Prevalence with the same superscripts could be statistically equated to each
ther at p > 0.05.pendence 134 (2014) 362– 369 363
with these SNPs on the trait of interest (Yang et al., 2010, 2011b).
When signiﬁcant, this would indicate that heritable variation in
the trait is at least partially captured by these SNPs in a highly
polygenic manner. Applying this methodology, investigators have
successfully attributed 23–51% of the variation in current smoking,
major depression, schizophrenia and human intelligence to genetic
inﬂuences (Davies et al., 2011; Lee et al., 2012; Lubke et al., 2012).
The  present study uses a multi-pronged phenotypic and
genomic approach to evaluate, respectively, the architecture and
genetic underpinnings of DSM-5 cannabis use disorders, deﬁned
as a quantitative phenotype. Instead of relying on a diagnostic
measure, we ﬁrst utilize item response models to construct a fac-
tor representing liability to DSM-5 cannabis use disorders, while
accounting for sex and ethnic differences. Second, we use this
psychometrically constructed factor score in a genome-wide asso-
ciation analysis. Finally, we  evaluate whether genome-wide SNPs
and putative causal variants in linkage disequilibrium with them
explain a signiﬁcant proportion of the heritable variation in DSM-5
cannabis use disorders.
2. Methods
2.1. Sample
The Study of Addictions: Genes and Environment (SAGE) includes 3988 indi-
viduals  ascertained from 3 study sources: the Collaborative Study of the Genetics
of  Alcoholism (N = 1410; Begleiter et al., 1995; Reich et al., 1998), the Collaborative
Study  of the Genetics of Nicotine Dependence (N = 1406; Bierut et al., 2007) and the
Family Study of Cocaine Dependence (N = 1172; Bierut et al., 2008). Further details
regarding  the study are available elsewhere (Bierut et al., 2010). The study includes
substantial  numbers of individuals who have used cannabis and experience prob-
lem use. For these analyses, data on 3053 (77% of the sample) individuals reporting
a  history of ever using cannabis were used.
2.2. Measures
2.2.1 DSM criteria. Twelve criteria from DSM-IV and DSM-5 (American
Psychiatric Association, 1994) were utilized (Table 1). These included DSM-IV abuse
criteria of (i) failure to fulﬁll major role obligations (role failure), (ii) recurrent use in
hazardous situations (hazard), (iii) recurrent social/interpersonal problems because
of use (social/interpersonal), and (iv) legal problems (legal), as well as the six DSM-IV
dependence criteria of (v) tolerance, (vi) using in larger quantities or for longer than
intended (larger/longer), (vii) persistent failed quit attempts (quit), (viii) spending
a  great deal of time using cannabis (time spent), (ix) giving up important activities
to  use cannabis (give up) and (x) experiencing physical or psychological problems
because  of cannabis use (problems). In addition, the two  DSM-5 criteria of (xi)
withdrawal  and (xii) craving were also used.
2.2.2 DSM-5 factor score
Based  on the factor analyses described below, a score representing liability to
DSM-5 cannabis use disorders was used as a quantitative index.
2.3.  Genotyping
The genotyping and quality control procedures applied to these data are
explained  in detail in earlier publications (Bierut et al., 2010; Laurie et al., 2010). In
brief, DNA samples from 3988 individuals were genotyped on the Illumina Human
1 M beadchip by the Center for Inherited Diseases Research (CIDR) at Johns Hop-
kins University. As described earlier, 948,658 SNPs passed data cleaning protocols.
No imputed data were used for these analyses. HapMap genotyping controls, dupli-
cates, related subjects, and outliers were removed. For the current analyses, data
on 3053 (77% of the sample) individuals reporting a lifetime history of cannabis use
were used. Self-identiﬁed ethnicity (consistent with analysis of genetic data) was
2018 European Americans and 1035 African Americans.
2.4.  Statistical analysis
2.4.1. Phenotypic factor analysis. We used MPlus (v5; Muthen and Muthen, 2007)
to conduct exploratory and conﬁrmatory factor analyses of the 12 DSM-IV/DSM-5
criteria  in the same sample. Exploratory analyses were conducted in the full sample,
while  subsequent conﬁrmatory factor analyses were conducted in African-American
(AA)  and European-Americans (EA), separately by sex, using a multi-group frame-
work.  Initially, factor loadings and thresholds were constrained across the ethnic
groups  and across sexes. Individual submodels were tested to determine whether
allowing  the factor loading and threshold for each criterion to vary across the groups
resulted in a signiﬁcant improvement in model ﬁt. The model that accommodated
3 hol De
a
s
2
e
i
t
(
p
a
w
p
A
w
2
t
2
p
G
w
t
a
s
2
T
g
y
e
A
c
r
3
3
r
3
r
a
5
m
o
D
d
a
t
A
u
t
p
D
r
e
a
n
u
t
m
(
c
w
w
u
e
c
f
e
Three genes surpassed the conservative gene-based Bonfer-
roni threshold of 2.8 × 10−6 in the EA, but not the AA subsample64 A.  Agrawal et al. / Drug and Alco
ll statistically signiﬁcant differences was used to generate factor scores that were
ubsequently used for genome-wide association analysis.
.4.2.  Genetic analyses. GWAS: A linear regression model, in the PLINK (Purcell
t  al., 2007) software package, was used. Genotype was coded log-additively (i.e.
ncreasing copies of the minor allele, selected from the full sample with ethnici-
ies  combined). Analyses were conducted separately in the EA (N = 2018) and AA
N = 1035) subsamples, adjusting for further ethnic differences via the inclusion of 2
rincipal components (generated via EIGENSTRAT; Price et al., 2006)). Other covari-
tes included age at interview (dummy-coded to represent the lower three quartiles
ith the oldest age group used as a reference), sex and study source (whether the
articipants were drawn from COGA, COGEND or FSCD). The results from the EA and
A subsamples were meta-analyzed in METAL (Willer et al., 2010) using effect size
eighting by the inverse of the standard errors.
.4.3. Gene-based association analysis. We used the Versatile Gene-based Associa-
ion  Study (VEGAS) program to conduct gene-based tests of association (Liu et al.,
010). VEGAS assigns individual SNPs to each of the 17,787 autosomal genes (by
hysical position on the UCSC hg18 Genome Browser assembly). p-Values from the
WAS are converted to upper-tailed chi-square statistics and then used to examine
hether  the chi-square distribution for each gene deviates from the null distribu-
ion.  Due to differing linkage disequilibrium patterns across ethnicities, gene-based
ssociation  was  conducted on results when EA (using CEU) and AA (using YRI)
ubjects  were analyzed separately.
.4.4. Estimation of total genomic variation (heritability). Genome-wide Complex
rait  Analysis (GCTA; Yang et al., 2011a) was used to estimate the proportion of
enomic variation explained by all SNPs available from the GWAS. Univariate anal-
ses were conducted for the factor score, and covariates (sex, age, study site and
thnicity as indexed by principal components) were included in all computations.
nalyses  were restricted to those of self-reported EA ancestry. Analyses were not
onducted in the AA subset because the modest sample size would likely have
esulted  in a large standard error.
. Results
.1. Sample characteristics
The  sample used for analyses was restricted to those who
eported at least one lifetime use of cannabis (N = 3053; 49% male;
2.5% from COGA, 38.5% from COGEND, 29% from FSCD; 66% self-
eported EA; mean age of 38.1 [18–68 years]). These individuals
re characterized with respect to the 12 individual DSM-IV/DSM-
 criteria in Table 1. Prevalence of each criterion was higher in
ales than females for both ethnic groups, and males, regardless
f ethnicity, were more likely than females to meet criteria for
SM-IV and DSM-5 diagnoses. However, several intriguing ethnic
ifferences emerged. For both sexes, hazardous use, use of larger
mounts or for a longer period of time and desire to quit or mul-
iple failed quit attempts were differentially endorsed by EA and
A. EA men  and women were more likely to endorse hazardous
se and less likely to endorse using larger amounts or for longer
han intended and failed quit attempts than their AA counter-
arts. In addition, tolerance, time spent using cannabis and the
SM-5 criteria of withdrawal and craving were more commonly
eported by AA women than their EA counterparts—similar differ-
nces were not noted for men. The prevalence of DSM-IV cannabis
buse/dependence was higher in men  compared with women, but
o within-sex ethnic differences were noted. For DSM-5, cannabis
se disorder was again more common in men  than women, and
here were no ethnic differences in men. However, AA women  were
ore likely to meet criteria compared with their EA counterparts
31.8% vs. 25.1%). Comparing the prevalence of DSM-IV vs. DSM-5
annabis use disorders—within each group, very modest changes
ere observed. Decrease in overall prevalence was noted for EA,
hile AA women showed a slight increase and AA men  remained
nchanged. Examining the [95%] conﬁdence limits for the point
stimates, only the decrease in prevalence in the EA was  statisti-
ally signiﬁcant (for men: 55.4% [52.2–58.6] vs. 51.1% [47.9–54.1];
or women: 28.1 [25.4–30.9] vs. 25.1% [22.6–27.9]) while the
stimates in AA subjects could be equated across diagnosticpendence 134 (2014) 362– 369
classiﬁcation scheme (for men: 52.6% [48.3–56.9] vs. 52.6
[47.2–55.8]; for women: 30.2% [26.2–34.4] vs. 31.8% [27.7–36.1]).
3.2.  Factor analysis
An  exploratory factor analysis of the full sample revealed that
a single factor solution provided a reasonable ﬁt to the data
(comparative ﬁt index (CFI): 0.996, root mean square error of
approximation (RMSEA): 0.054). While a 2-factor exploratory solu-
tion modestly improved these ﬁt indices (e.g., 2 factor solution:
CFI: 0.999, RMSEA: 0.036), the inter-factor correlation was 0.90.
Hence, we  proceeded with the more parsimonious single factor
conﬁrmatory analysis, which readily approximates item response
parameters. Conﬁrmatory factor analysis of the 4 DSM-IV abuse, 6
DSM-IV dependence and the DSM-5 withdrawal and craving crite-
ria revealed high factor loadings (0.75–0.90) for all criteria except
legal problems (0.23), which was excluded (consistent with DSM-5)
from further analyses comparing factor loadings and thresholds for
each individual criterion across EA and AA males and females. The
factor loadings and thresholds (all signiﬁcant at p < 0.0001) from
the model allowing for statistically signiﬁcant differences across
individual items are shown in Table 2. Factor loadings and thresh-
olds could not be constrained across the groups for hazardous
use, interpersonal problems, withdrawal, using more than intended
(larger/longer), repeated/failed quit attempts, time spent and phys-
ical/psychological problems (please see supplemental eTable 1
for ﬁt indices1). Factor scores that accommodated these differing
thresholds and factor loadings were created for each of the four
subgroups and used for genomic analyses.
3.3. GWAS
Individual signals did not surpass the Bonferroni corrected
genome-wide signiﬁcance threshold of p < 5 × 10−8. The results for
the top 20 SNPs are presented in Table 3 (the top 100 results
for the EA and AA subsamples are available in e Tables 2 and 3,
respectively2). For the EA subsample, 11 SNPs on 17q23-24
appeared to be associated at nominal levels of signiﬁcance although
none surpassed the genome-wide threshold of 5 × 10−8.The top
SNP, rs6504555, was  an intronic variant in the bromodomain PHD
ﬁnger transcription factor (BPTF) gene—a regional association plot
for this region of chromosome 17 is shown in Fig. 1, indicating a high
degree of linkage disequilibrium across the associated SNPs. With
the exception of rs11870068, the remaining chromosome 17 SNPs
were in moderate to high linkage disequilibrium (r2 ranging 0.66
to 1.0). In the AA subsample, results did not aggregate in any par-
ticular chromosomal region. The most signiﬁcant SNP, rs4364205,
on chromosome 3, was intergenic.
Meta-analysis of the results from the EA and AA subsamples did
not yield a boost in statistical signiﬁcance (Table 3). This was  evi-
dent from a comparison of results in the EA and AA subsamples.
Of all SNPs with p-values < 0.05 in EA subsample, only 5% had cor-
responding p-values < 0.05 in AA subsample. However, particularly
for the SNPs for the EA subsample shown in Table 2, the direction
of effect in the AA subsample predominantly (with the exception
of 5 of 20 SNPs) concurred with the EA subsample.
3.4. Gene-based association results1 Supplementary material can be found by accessing the online version of this
paper  at http://dx.doi.org and by entering doi:...
2 Supplementary material can be found by accessing the online version of this
paper  at http://dx.doi.org and by entering doi:...
A. Agrawal et al. / Drug and Alcohol Dependence 134 (2014) 362– 369 365
Table  2
Standardized factor loadings [95% conﬁdence intervals] from one factor conﬁrmatory factor analysis in 3053 lifetime cannabis users of European-American (EA) and African-
American (AA) ancestry.
Males Females
EA AA EA AA
Role obligations 0.90 0.90 0.90 0.90
[0.87–0.92] [0.87–0.92] [0.87–0.92] [0.87–0.92]
Hazard 0.83  0.73* 0.83 0.71*
[0.78–0.88] [0.64–0.82] [0.78–0.88] [0.60–0.82]
Social/Interpersonal 0.92  0.90 0.89 0.89
[0.88–0.95]  [0.85–0.95] [0.85–0.94] [0.82–0.96]
Tolerance 0.87  0.87 0.87 0.87
[0.85–0.90] [0.85–0.90] [0.85–0.90] [0.85–0.90]
Withdrawal 0.88 0.85 0.92 0.93
[0.83–0.93]  [0.78–0.92] [0.88–0.96] [0.89–0.98]
Larger/Longer 0.84  0.89 0.91 0.91
[0.79–0.90]  [0.84–0.94] [0.87–0.95] [0.86–0.97]
Quit 0.75* 0.73* 0.85 0.79*
[0.69–0.82] [0.63–0.83] [0.80–0.90] [0.70–0.88]
Time Spent 0.87 0.90 0.92 0.94
[0.82–0.91]  [0.84–0.94] [0.88–0.96] [0.89–0.93]
Give up 0.92 0.92 0.92 0.92
[0.89–0.94] [0.89–0.92] [0.89–0.94] [0.89–0.94]
Problems 0.91  0.90 0.92 0.84
[0.88–0.95]  [0.84–0.95] [0.88–0.96] [0.75–0.92]
Craving 0.90  0.90 0.90 0.90
[0.88–0.93]  [0.88–0.93] [0.88–0.93] [0.88–0.93]
Mean Factor Score 0.49 0.50 −0.23 0.00
[0.31–0.67]  [0.30–0.69] [−0.42–0.05] [Reference]
Note: If factor loadings could be constrained, then they are shown as such. Differing factor loadings may  not statistically differ from each other [i.e. as indicated by overlapping
conﬁdence limits] but may have been unconstrained in models because of differing thresholds.
* Those factor loadings with an * could be equated to each other but not to other estimates.
F ican s
o rsion 
(
s
5
M
s
g
tig. 1. Regional association plot of chromosome 17 results from the European-Amer
f the references to colour in this ﬁgure legend, the reader is referred to the web  ve
Table 4). In the EA subsample, association was noted on chromo-
ome 17q23-24 for C17orf158 (chromosome 17 open reading frame
8), and the adjacent genes BPTF and PPM1D (protein phosphatase
g2+/Mn2+ dependent, 1D). Multiple other neighboring genes also
howed aggregation of association signals although none surpassed
ene-based correction. As VEGAS allows for SNPs to be assigned
o the 50 kb region ﬂanking the gene (footprint), this clustering ofubsample. SNP with lowest p-value (diamond-shape, in purple). (For interpretation
of this article.)
genes  might be attributed to SNPs being assigned to the footprints
of multiple neighboring genes. The association appeared to be spe-
ciﬁc to the EA subsample with corresponding p-values >0.05 in the
AA subsample. For results from the AA subsample, the lowest p-
value for the gene-based association test was 0.00013 for Patched
domain containing 3 (PTCHD3), which had a corresponding p-value
of 0.61 in the EA results.
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Table  3
Top  20 association results from genome wide association study of the DSM-5 cannabis use disorders factor scores in 2018 European-American and 1035 African-American
lifetime cannabis users. Also shown are p-values from a meta-analysis of the results from both ethnic groups.
Chromosome SNP Gene Allele Frequency Beta Lower
95%
Upper  95% p-value p-value
other*
Dir. Meta p-value
European-Americans
17 rs6504555 BPTF A 0.22 0.15 0.09 0.20 1.73E–06 0.35 ++ 2.00E–05
X rs7884312 DMD A 0.12 0.21 0.13 0.30 1.73E–06 0.87 +− 1.59E–03
X rs7880016 DMD A 0.11 0.22 0.13 0.31 2.65E–06 0.53 +− 6.43E–03
17 rs8071463 BPTF G 0.22 0.14 0.08 0.20 3.25E–06 0.29 −− 2.16E–05
2 rs3731808 PDE11A T 0.01 −0.58 −0.83 −0.33 4.82E–06 0.47 −+ 5.14E–04
12 rs10082916 RARG T 0.04 −0.27 −0.39 −0.15 4.84E–06 0.60 −− 4.93E–04
12 rs12307672 RARG A 0.04 −0.27 −0.39 −0.15 4.84E–06 0.71 −− 9.12E–04
17 rs9897982 BPTF T 0.22 0.14 0.08 0.20 5.10E–06 0.60 ++ 1.29E–04
17 rs3935969 BPTF C 0.22 0.14 0.08 0.20 5.13E–06 0.16 −− 1.35E–05
17 rs2365468 BPTF T 0.22 0.14 0.08 0.20 5.40E–06 0.55 ++ 1.12E–04
17 rs9890629 BPTF A 0.22 0.14 0.08 0.20 5.52E–06 0.15  ++ 1.26E–05
17 rs8074078 BPTF G 0.22 0.14 0.08 0.20 5.65E–06 0.15 −− 1.19E–05
17 rs11870068 BPTF C 0.22 0.14 0.08 0.20 5.80E–06 0.17 −+ 1.84E–03
12 rs11065202 C 0.42 0.11 0.06 0.16 5.91E–06 0.95 −+ 2.39E–04
17 rs9891146 C17orf58 T 0.28 0.13 0.07 0.18 6.42E–06 0.98 ++ 3.04E–04
17 rs6504548 BPTF C 0.22 0.14 0.08 0.20 6.49E–06 0.59 −− 1.41E–04
12 rs2066938 MGC5139 G 0.27 0.13 0.07 0.18 6.86E–06 0.09 −− 3.16E–06
17 rs7208663 BPTF C 0.22 0.14 0.08 0.20 7.13E–06 0.17 −− 1.85E–05
8 rs12056774 T 0.23 0.13 0.07 0.19 7.71E–06 0.46 ++ 9.16E–05
22 rs165685 PCQAP T 0.18 0.15 0.08 0.21 9.31E–06 0.65 ++ 2.16E–05
African–Americans
3 rs4364205 T 0.41 −0.19 −0.26 −0.12 1.30E–07 0.06 −+ 1.10E–01
1 rs16853258 G 0.07 −0.34 −0.47 −0.20 1.06E–06 0.16 +− 1.87E–06
11 rs1981990 A 0.30 0.19 0.11 0.26 2.62E–06 0.80 +− 8.70E–03
2 rs7601137 AFF3 C 0.14 0.25 0.14 0.35 3.39E–06 0.62 ++ 2.61E–03
8 rs2410545 NAT1 A 0.12 −0.27 −0.39 −0.16 4.08E–06 0.87 −+ 7.50E–02
2 rs12479422 A 0.09 0.30 0.17 0.42 4.57E–06 0.29 −− 2.18E–04
8 rs11203943 NAT1 A 0.05 −0.38 −0.54 −0.22 4.67E–06 0.32 ++ 2.85E–03
10 rs493965 A 0.48 −0.17 −0.24 −0.10 5.83E–06 0.52 −+ 3.11E–02
8 rs6586712 NAT1 G 0.12 −0.26 −0.37 −0.15 8.95E–06 0.64 +− 1.56E–01
8 rs16871627 T 0.17 −0.21 −0.31 −0.12 9.41E–06 0.43 −+ 1.40E–05
2 rs865108 STEAP3 G 0.47 0.17 0.09 0.24 9.56E–06 0.54 −+ 4.74E–02
22 rs9627601 TBC1D22A C 0.15 −0.23 −0.33 −0.13 1.01E–05 0.23 +− 2.47E–05
14 rs11850171 G 0.23 0.19 0.10 0.27 1.18E–05 0.92 ++ 1.31E–05
3 rs6774262 A 0.43 0.16 0.09 0.24 1.30E–05 0.19 −− 2.13E–04
1 rs950601 A 0.16 −0.22 −0.32 −0.12 1.63E–05 0.20 ++ 1.35E–03
1 rs6677326 G 0.04 0.40 0.22 0.58 1.69E–05 0.87 −+ 2.30E–05
10 rs2815527 G 0.42 0.16 0.09 0.24 2.00E–05 0.67 ++ 6.75E–03
22 rs12170279 TBC1D22A G 0.20 −0.20 −0.29 −0.11 2.20E–05 0.30 +− 4.59E–05
7 rs12668723 A 0.21 0.19 0.10 0.27 2.33E–05 0.12 −− 1.41E–04
10 rs2815523 G 0.42 0.16 0.09 0.24 2.54E–05 0.68 ++ 7.58E–03
2 rs7557254 C 0.37 −0.16 −0.24 −0.09 2.60E–05 0.14 −− 2.50E–05
*p-value other indicates the p-value for that SNP in the other ethnicity (i.e. AA p-value for analyses conducted in European-Americans and vice versa).
Table  4
Top  10 genes showing association via gene-based association analysis in European- and African-American subsamples analyzed separately.
Gene Chromosome Start basepair End basepair p-value (EA) p-value (AA)
European-American subsample (N = 2018)
C17orf58 17 63,417,678 63,420,227 <1E–6 0.422
PPM1D  17 56,032,335 56,096,818 <1E–6 0.149
BPTF  17 63,252,241 63,410,956 0.000001 0.351
UNC119B  12 11,963,221 11,964,582 0.000016 0.11
LRRC37A3  17 60,280,949 60,345,365 0.000026 0.618
ACADS  12 11,964,795 11,966,219 0.000027 0.119
KIAA0152  12 11,960,933 11,962,405 0.000033 0.136
MYEF2  15 46,218,920 46,257,850 0.000137 0.944
CABP1  12 11,956,280 11,958,951 0.000161 0.288
ZNF681  19 23,713,836 23,733,533 0.000164 0.24
African-American subsample (N = 1035)
PTCHD3 10 27,727,122 27,743,303 0.000125 0.61
AFF3  2 99,530,147 10,012,546 0.000381 0.466
FILIP1L  3 10,103,467 10,131,603 0.000415 0.224
C3orf26  3 10,101,937 10,138,013 0.000527 0.215
CNOT10  3 32,701,701 32,790,358 0.000556 0.171
FANCM  14 44,674,885 44,739,843 0.000565 0.407
IAPP  12 21,417,084 21,423,683 0.000588 0.493
NMUR2  5 15,175,129 15,176,503 0.000603 0.674
FKBP3  14 44,654,858 44,674,272 0.000668 0.311
CCDC91  12 28,301,399 28,594,366 0.000686 0.257
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.5. Total genomic variation (heritability)
Genomic variation was responsible for 21% (SE = 17.7) of the
henotypic variance in the factor score. However, the estimate was
ot statistically signiﬁcant (p = 0.13).
.  Discussion
We  sought to examine the phenotypic and genomic architecture
f a continuously distributed cannabis use disorders factor, psycho-
etrically derived from DSM-5 criteria, in samples ascertained for
lcohol, nicotine and cocaine dependence. Our analyses revealed a
igh degree of support for the unidimensionality of cannabis use
isorders. Analysis of ethnic differences indicated a modest reduc-
ion in the prevalence of DSM-5 cannabis use disorders, relative to
SM-IV, in EA. Genomic analyses, using a genome-wide scan, failed
o identify SNPs that satisﬁed statistical thresholds for signiﬁcance;
owever, gene-based association implicated genes on the q-arm
f chromosome 17. A genome wide variance calculation revealed
hat 21% of the phenotypic variance in cannabis use disorders was
aptured by the available common variation on the genome-wide
rray, but this estimate had a large standard error and was not
igniﬁcant.
We used the factor score as our phenotype for genomic analyses.
ncorporating withdrawal and craving, excluding legal problems
nd combining across DSM-IV abuse and dependence criteria, this
actor embodies the ‘spirit’ of the new DSM-5 diagnostic scheme
hile not being encumbered by concerns that the threshold of
 or more criteria for diagnosis of disorder is too lax (Martin
t al., 2011b). From a psychometric perspective, our results are
onsistent with the extant literature (see Hasin et al., 2013 for a
omprehensive overview). For instance, despite our sample being
scertained for alcohol, nicotine and cocaine dependence, which
nﬂated endorsement rates of individual criteria (i.e. due to the
igh comorbidity across substance use disorders), our high rates
f hazardous use were comparable with those reported for lifetime
annabis users from the general population as reﬂected in data from
he National Epidemiological Survey of Alcohol and Related Condi-
ions (Agrawal and Lynskey, 2007; Compton et al., 2009). Likewise,
roadly consistent with numerous other studies, the DSM-IV abuse
riterion of legal problems was infrequently endorsed and had a
eak factor loading, afﬁrming its proposed exclusion from DSM-
. The overall prevalence of the remaining criteria, although much
igher than in general population cohorts, supports the presence
f a unidimensional construct across sexes and ethnicities. Craving
nd withdrawal, both of which have been added to DSM-5, per-
ormed well, with high factor loadings supporting their inclusion.
Overall,  rates of diagnostic DSM-5 cannabis use disorders appear
o be modestly lower than those for DSM-IV abuse/dependence,
ut only in EA, particularly men. This ﬁnding is highly comparable
ith epidemiological analyses of alcohol symptomatology in U.S.
Agrawal et al., 2010; Martin et al., 2011a; Verges et al., 2011) and
ith results from the 2007 Australian National Survey of Mental
ealth and Wellbeing, which reported a decrease in the lifetime
ate of cannabis use disorder from 6.2% to 5.4% when transitioning
rom DSM-IV to DSM-5 (Mewton et al., 2013). In our sample, this
ecrease was uniformly attributable to individuals who endorsed
azardous use alone, which results in a DSM-IV diagnosis of
annabis abuse but not a DSM-5 diagnosis of cannabis use dis-
rder, because it falls below the latter’s minimum two-symptom
hreshold. No differences were noted in AA men  (or women), and
his is also not surprising. Individuals endorsing this criterion alone
end to be of higher socio-economic standing (Keyes and Hasin,
008) and tend to, overwhelmingly, endorse this criterion due
o a history of drinking and driving (Agrawal et al., 2011a). Thatpendence 134 (2014) 362– 369 367
socio-economic status may  correlate with ethnicity is expected—in
our data, 45.9% of AA participants reported a gross annual income
of less than $20,000, vs. 15.4% of their EA counterparts.
Upon examining gender and ethnic differences within classiﬁ-
cation version (e.g., DSM-5 diagnoses across males and females),
the only signiﬁcant variation was  noted for DSM-5 diagnoses in AA
women  who were more likely to receive a diagnosis of DSM-5, but
not DSM-IV cannabis use disorder, relative to their EA female coun-
terparts. Intriguingly, also relative to their EA counterparts, they
were less likely to endorse hazardous use but more likely to endorse
numerous other criteria, with the exception of giving up important
activities and use despite physical/psychological problems. This
ﬁnding may  be attributable to the larger number of AA women
that were ascertained from the cocaine dependence study (46%
AA vs. 18.5% EA women  are drawn from FSCD) vs. other studies.
Although this observation holds true for the men as well, and the
prevalence (or mean number of symptoms endorsed) did not vary
across AA and EA women, it is possible that AA women (but not men
or EA women) from the FSCD study represent a high-risk group.
For instance, when compared to the alcohol and nicotine depend-
ence studies, AA women  from the cocaine (FSCD) study were more
likely to report lower household income (59.6% vs. 34.4%) and a
greater likelihood of less than a high school education (32.6% vs.
17.4%). Thus, this vulnerability might reﬂect environmental adver-
sity rather than increased genetic susceptibility, and in any case,
is accounted for in the genomic analyses by incorporating study
sample and gender as covariates.
From  a genetic perspective, the single SNP analyses did not
reveal any genome wide signiﬁcant signals. This is likely because
our sample is underpowered, even with a quantitative trait, to
detect single variants of modest effect size. Using GWAPower (Feng
et al., 2011), we  estimated power available in our dataset to iden-
tify SNPs of varying effect size. Power was 80% when an effect size
of 0.01 (1%) was anticipated (with covariates explaining about 20%
of the variance, and Type 1 error set at 5 × 10−8). Increasing efforts
to amass larger samples with comparable cannabis-related data
would afford greater power to detect variants of more modest effect
size via meta- and mega-analyses. However, few current studies
have DSM-5 criteria data. In this regard, factor scores (or symp-
tom counts) such as ours may  prove to be useful phenotypes as
they can accommodate DSM-IV and DSM-5 based assessments of
vulnerability to cannabis use disorders.
In contrast, the gene-based analyses conducted with the EA sub-
sample identiﬁed a cluster of genes, of varied function, on the q-arm
of chromosome 17 that appeared to contain an aggregation of vari-
ants associated with DSM-5 cannabis use disorders. The genes that
surpassed gene-based correction were C17orf58, BPTF and PPM1D.
PPM1D is in a region of chromosome 17 that is well documented
to be ampliﬁed in breast cancer (Bernards, 2004), and the gene
itself belongs to a family of serine/threonine phosphatases that are
involved in stress signaling (Lowe et al., 2012). On the other hand,
BPTF was originally identiﬁed in brain homogenates from deceased
Alzheimer’s patients (Jordan-Sciutto et al., 2000). It is putatively
involved in chromatin remodeling (Landry et al., 2008). We  hesitate
to speculate about the potential role of these genes in the etiology
of cannabis use disorders.
Contradictory to the extant twin literature positing 50%
heritable variation in cannabis use disorders, the aggregate
effects of SNPs on the array captured 21% of genetic varia-
tion; however, this estimate was  not statistically signiﬁcant.
The lack of signiﬁcance is primarily due to our sample size.
For instance, with cigarette smoking, a sample size of 4181
yielded a heritability estimate of 19% at p = 0.024 (Lubke et al.,
2012). It is, however, worth noting that similar to other major
psychiatric disorders (Lee et al., 2013), common variation on
commercial arrays does not capture all the postulated heritability
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n complex traits. This may  be attributable to imperfect linkage
isequilibrium between these SNPs and rarer causal variants or
ue to other factors, such as epistasis, gene-environment interplay
nd other variation (e.g., copy number variants).
Some other limitations of the present study are worth noting.
irst and foremost, the present sample was ascertained from three
amily studies of substance use disorders for the express purpose
f identifying genetic variants for alcoholism, nicotine and cocaine
ependence and related psychopathology. Hence, the psychomet-
ic analyses may  not generalize to other cohorts with different
scertainment criteria. Second, while we were able to include a
easure of cannabis withdrawal in the analysis, the symptoms and
iagnostic scheme (i.e. 3 or more of 7 withdrawal symptoms) used
o assess withdrawal do not conform to those in DSM-5. This was
navoidable since all studies predated the DSM-5 by a considerable
umber of years. However, analyses using the DSM-5 criteria in an
ndependent twin sample do not indicate any evidence for genetic
nﬂuences on DSM-5 withdrawal that do not overlap with DSM-IV
annabis abuse/dependence (Verweij et al., 2012).
From a clinical and public health standpoint, it is also reassur-
ng to note that a transition from DSM-IV to DSM-5 will likely
nvolve only a modest alteration in prevalence of diagnosed indi-
iduals. However, future studies, particularly those aggregating
ndividual-level genotypic and phenotypic data across multiple
amples should explore the extent to which individual DSM-IV, and
n particularly, the new DSM-5 criteria contribute to speciﬁcity of
enetic signals identiﬁed.
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